Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.

Abstract

BACKGROUND/AIM:

Rectal cancer is a recalcitrant disease with limited treatment options. Pre-clinical studies have shown the efficacy of methionine restriction with a low-methionine diet and oral recombinant methioninase (o-rMETase) for colorectal cancer. There are also clinical studies on methionine restriction with o-rMETase for other recalcitrant cancer types. The goal of the present study was to determine the efficacy of a low-methionine diet and o-rMETase on a rectal cancer patient.

PATIENT AND METHODS:

A 55-year-old man diagnosed with recurrent locally-advanced rectal-cancer was treated with o-rMETase and a low-methionine diet, during which time, he did not receive standard chemotherapy. Disease stability was monitored by carcinoembryonic antigen (CEA) levels, sigmoidoscopy, and computed tomography (CT).

RESULTS:

The patient was diagnosed with stage II rectal cancer (adenocarcinoma) in 2018. After neoadjuvant chemoradiotherapy, the patient received total mesorectal excision (TME) in 2018. Local recurrence was found by sigmoidoscopy one year later. The patient was given chemotherapy, the recurrent lesion shrunk, and was then removed endoscopically in December 2019, with positive margins. The tumor did not become apparent for about a year after that. An endoscopic examination performed in December 2020, revealed a local recurrence. Since that time, the patient had an elevated CEA. The patient went on o-rMETase and a low-methionine diet from January 2021. Since then, the patient's CEA level has remained stable for the next year and a half. He received sigmoidoscopy and CT regularly, and the tumor size has not changed.

CONCLUSION:

This patient's clinical course indicates that o-rMETase and a low-methionine diet may be effective for rectal cancer, for long-term disease stabilization. Further case studies and clinical trials are needed to determine the generality of the present result.

• Authors: Yutaro Kubota, Qinghong Han, Kazuyuki Hamada, Yusuke Aoki, Noriyuki Masaki, Koya Obara, Takuya Tsunoda, Robert M Hoffman
• Journal: Anticancer research (Anticancer Res) Vol. 42 Issue 8 Pg. 3857-3861 (Aug 2022) ISSN: 1791-7530 [Electronic] Greece
• PMID: 35896248 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Carcinoembryonic Antigen
• Recombinant Proteins
• Methionine
• Carbon-Sulfur Lyases
• L-methionine gamma-lyase

Topics

• Carbon-Sulfur Lyases (therapeutic use)
• Carcinoembryonic Antigen
• Diet
• Humans
• Male
• Methionine
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Recombinant Proteins (therapeutic use)
• Rectal Neoplasms (drug therapy)